ProQuant™, a world-leading proteomics platform delivering unparalleled quantitative accuracy

ProQuant™, a world-leading proteomics platform delivering unparalleled quantitative accuracy

Welcome to ProQuant™

ProQuant™ is a world-leading proprietary platform for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples, delivering quantitative accuracy unachievable with any other technology.  The step-change in quantitative performance unleashes the promised power of proteomics, and the platform is now being provided by RxCelerate with the power to speed up and de-risk multiple phases of the drug development pipeline.

CUSTOM PROJECTS

We will apply our proprietary platform and expertise to design and provide custom proteomics projects designed for just one thing – to provide the solution to your questions.

NO BIAS

All of our proprietary methods and custom algorithms are unsupervised, meaning no bias can be introduced into your data.

ProsaRX RxNfinity

PART OF A BIGGER FAMILY

RxCelerate are able to provide fully integrated programmes for drug discovery from small molecule or antibody design right through to preclinical studies and beyond.

Our Services

ProQuant™ has many different applications including:

Target identification

Biomarker identification

Biologics development and CMC

Label characterisation

Chemoproteomics

PTM characterisation

Our Platform

ProQuant™ is a bottom-up proteomics platform, performing high resolution LC-MS/MS analysis of proteins.  We have evaluated and optimised each stage of the process to be as quantitative as possible.  This has resulted in a proprietary proteomics process that has exceptional quantitative reproducibility.  In tests we have replicate CVs of <20% for over 80% of the proteins quantified in a complex biological sample – with this replicate reproducibility including the entire protocol: sample preparation, digestion, LC-MS/MS and data processing.  This exceptional level of performance not only improves outcomes for traditional applications but expands the range of applications in which it can be used.

About RxCelerate

ProQuant™ is a new offering introduced after acquisition of the proteomics team from Methuselah Health in 2022.  RxCelerate was founded in 2013 with a vision to provide a bespoke high-quality outsourced drug discovery and development platform.  Originally focused on delivering preclinical and in vitro biology services, during the last nine years we have expanded our in-house capabilities to include chemistry, in silico design, systems biology and project and programme management.

Got an Enquiry?

    Keep up to date

    Find out the latest news and updates from RxCelerate, RxBiologics and ProsaRx by following us on social media:

    Get in touch

    Call Us 01223 839557
    Email Us info@proquant.bio

    Visit Us

    RxCelerate Ltd
    Dorothy Hodgkin Building,
    Babraham Research Campus,
    Babraham, Cambridge CB22 3FH

    rxcelerate